Peptides with skin condition improving activity and their uses

Abstract

The present application relates to a peptide having skin condition-improving activity and its uses, and provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1, and a cosmetic composition for improving skin condition that contains the peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Description

Technical Field

[0001] The present application relates to a peptide having skin condition-improving activity and use thereof.

Background Art

[0002] Human skin constantly undergoes changes, among which the most representative is the decreased function of skin and reduced visual beauty caused by aging. Aging induces the formation of skin wrinkles, and representative factors for wrinkle formation include ultraviolet exposure and reduced collagen biosynthesis. Skin aging is broadly classified into intrinsic aging caused by genetic factors and extrinsic aging caused by external environmental factors such as solar radiation. Among these, it is known that for extrinsic aging, aging can be prevented, treated or delayed through the elimination of reactive oxygen species, proliferation of fibroblasts and promotion of collagen biosynthesis, etc.

[0003] On the other hand, collagen, which is a major component of the extracellular matrix, is a major matrix protein produced by dermal fibroblasts. Collagen forms most of the organic materials of skin, tendons, bones and teeth, and particularly has a high content in bones and skin (dermis). Such collagen decreases with age and photoaging caused by ultraviolet irradiation, which is known to be closely associated with skin wrinkle formation. In addition, collagen plays an important role in wound healing, and promoting collagen synthesis in damaged epithelium can enable rapid recovery of wounds without scarring. Meanwhile, it has been reported that when the compactness of the basal layer etc. is increased due to the promotion of collagen biosynthesis, the concentration of melanin pigment per unit skin density decreases, so an effect of brightening skin tone can be expected.

[0004] Under such technical background, multifaceted studies have been conducted to improve skin conditions through mechanisms such as promoting collagen biosynthesis, proliferating fibroblasts and increasing their activity (Korean Registered Patent No. 10-1813629), but the current situation still has deficiencies.

Summary of the Invention

[0005] One embodiment is to provide a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0006] Another embodiment provides a skin condition improving composition containing a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0007] Other purposes and advantages of this application will be further clarified by the following detailed description, along with the claims and drawings. Any matters not described herein are readily apparent and inferable to those skilled in the art of this application or similar art, and are therefore omitted from this description.

[0008] [Technical solution] Each description and embodiment disclosed in this application may also apply to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not considered to be limited by the specific descriptions described below.

[0009] One embodiment provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0010] As used herein, the term "peptide" may mean a linear molecule formed by the linking of amino acid residues by peptide bonds. Such peptides can be produced by chemical synthesis methods known to those skilled in the art, particularly by solid-phase or liquid-phase synthesis techniques (US Patent No. 5,516,891). The inventors, through diligent efforts to develop a peptide with biologically effective activity, have identified a peptide consisting of the amino acid sequence of Sequence ID No. 1. Here, the biologically effective activity also exhibits one or more properties selected from those such as (a) promotion of fibroblast proliferation; (b) enhancement of the expression of extracellular matrix components such as collagen type 1 (Col1a1), fibronectin, or elastin; and (c) enhancement of the expression of skin barrier factors such as sirtuin-1 (SIRT-1) or aquaforin-3 (AQP3). Therefore, such peptides can be utilized for applications in improving skin conditions.

[0011] The peptide may also have a protecting group attached to its N or C terminus to acquire chemical stability, enhanced pharmacological properties (half-life, water absorption, potency, efficacy, etc.), altered specificity (e.g., broad biological activity spectrum), or reduced antigenicity. In one specific example, the N terminus of the peptide may have an acetyl group, a fluorenyl methoxycarbonyl group, or a fluorenyl methoxycarbonyl group. en The peptide is bonded to one protecting group selected from the group consisting of ylmethoxycarbonyl group, formyl group, palmitoyl group, myristyl group, stearyl group, butoxycarbonyl group, allyloxycarbonyl group, and polyethylene glycol (PEG); and / or the C-terminus of the peptide is an amino group (-NH2), The three class Alkyl group (tertiary alkyl group) and Hydrazino ( hydrazino The peptide may be conjugated with any one protecting group selected from the group consisting of , -NHNH2). The peptide may also selectively further include a targeting sequence, a tag, labeled residues, or an amino acid sequence manufactured for a specific purpose to increase half-life or peptide stability.

[0012] The peptides are artificially synthesized, non-naturally occurring, or engineered, where “non-naturally occurring or engineered” means a state produced by artificial modification rather than the state of existence that occurs naturally. Here, the artificial modification may include artificially synthesizing an amino acid sequence by mimicking multiple amino acid structures, or being engineered to acquire chemical stability, enhanced pharmacological properties, altered specificity, or reduced antigenicity, as described above.

[0013] As used herein, the term "stability" may refer not only to in vivo stability, which protects the peptide from attack by endogenous protein-cleaving enzymes, but also to storage stability (e.g., room temperature storage stability).

[0014] Another embodiment provides a cosmetic composition for improving skin condition that contains a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0015] As stated above, any terms or elements mentioned in the description of the peptides that are the same as those already mentioned are as described above.

[0016] As used herein, the term “improvement” may mean any action that alleviates or treats a condition, such as any action that at least reduces the severity of a symptom.

[0017] As used herein, the term "improvement of skin condition" comprehensively refers to the process or effect of treating, reducing, or mitigating skin damage induced by intrinsic or extrinsic factors of the skin, and may, but is not limited to, wrinkle reduction, improved skin elasticity, wound healing, strengthening of the skin barrier, or inhibition of skin aging.

[0018] Here, "wrinkle improvement," "skin elasticity improvement," and "wound healing" can refer to all effects that increase the total amount of extracellular matrix factors, including collagen synthesis promotion. Furthermore, "strengthening the skin barrier" can refer to enhancing the skin's natural functions, such as preventing leakage of moisture and nutrients from the skin and preventing the penetration of harmful substances like bacteria and viruses. Additionally, "suppression of skin aging" can refer to suppressing the decline of skin function, such as wrinkles, sagging, and loss of elasticity. In this context, the aforementioned skin aging also includes photoaging, such as skin aging caused by ultraviolet radiation.

[0019] Conventional functional peptides, despite their effective biological activity, suffer from disadvantages such as not being effectively absorbed into target tissues or cells due to their size, or being eliminated from the body quickly due to their short half-life. On the other hand, the cosmetic composition according to one example contains a peptide consisting of 10 or fewer amino acids as an active ingredient, resulting in excellent skin penetration of the active ingredient. For example, when applied topically to the skin, it can effectively improve skin condition.

[0020] According to one embodiment, it was possible to promote the proliferation of fibroblasts and improve the synthesis of extracellular matrix components and skin barrier factors. Therefore, the peptide can be used as an active ingredient in cosmetic compositions for improving skin condition.

[0021] The cosmetic composition may, but is not limited to, contain a cosmetically effective amount of the peptide and / or a cosmetically acceptable carrier.

[0022] As used herein, the term "cosmetically effective amount" means an amount sufficient to achieve the skin condition-improving effect of the cosmetic composition.

[0023] The weight ratio between the peptide and a cosmetically acceptable carrier is, for example, 500:1 to 1:500; by way of example, the weight ratio may be 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2, but is not limited thereto.

[0024] The cosmetic composition may be prepared into any dosage form conventionally produced in the art, and may be formulated into, for example, but not limited to, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansers, oils, powder foundations, emulsion foundations, wax foundations and sprays. For example, it may also be prepared into dosage forms of softening lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.

[0025] When the dosage form of the cosmetic composition is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or the like may be used as a carrier component.

[0026] When the dosage form of said cosmetic composition is powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder is used as a carrier component; for example, in the case of a spray, the composition may further comprise a propellant such as chlorofluorohydrocarbon, propane / butane or dimethyl ether.

[0027] When the dosage form of said cosmetic composition is a solution or an emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, and the composition may for example comprise water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.

[0028] When the dosage form of said cosmetic composition is a suspension, usable carrier components include liquid diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, and microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, etc.

[0029] When the dosage form of said cosmetic composition is a surfactant-containing cleansing product, usable carrier components include aliphatic alcohol sulfates, aliphatic alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazolinium derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulfates, alkyl amido betaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters, etc.

[0030] The peptide may be contained in nanosomes or nanoparticles to further improve skin penetration or stability issues. For example, the nanosomes may be produced by a microfluidizer using lecithin as a raw material and contained within lecithin particles. Any known method for producing the nanosomes may be used. The size of the nanosome particles is preferably 30 to 200 nm. If the size of the nanosome particles is less than 30 nm, skin penetration proceeds very quickly, causing skin side effects, and if it exceeds 200 nm, skin penetration is not easy, making it difficult to obtain the benefits of using the nanosome structure.

[0031] In addition to the peptide and carrier components as active ingredients, the components contained in the cosmetic composition may include ingredients commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances.

[0032] The content of peptides as active ingredients in the cosmetic composition can be appropriately and non-restrictively selected depending on the product form, desired use, etc., and can be added in amounts of, for example, 0.01 to 15% by weight of the total weight of the cosmetic composition. Alternatively, for example, the cosmetic composition may contain peptides in amounts of 1.0% to 3.0% by weight, preferably 2.0% to 3.0% by weight, based on the total weight.

[0033] Further embodiments include a method for improving skin condition, comprising the step of applying a cosmetic composition containing a peptide comprising the amino acid sequence of SEQ ID NO: 1 as an active ingredient to the skin of an individual; and providing uses for the peptide comprising the amino acid sequence of SEQ ID NO: 1 for the production of compositions for improving skin condition.

[0034] As stated above, any terms or elements mentioned in the description relating to the cosmetic composition that are the same as those already mentioned are as described above.

[0035] As used herein, the term “individual” means an individual subject requiring improvement of skin condition, and more specifically, a mammal such as a human or non-human primate, mouse, dog, cat, horse, and cattle.

[0036] As used herein, the terms “apply,” “administer,” and “coat” are interchangeable and may mean bringing a composition according to one embodiment to a desired site at least partially, or placing a composition according to one embodiment within an individual via an administration route.

[0037] Another embodiment provides an antioxidant composition containing a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0038] As stated above, any terms or elements mentioned in the description of the peptides that are the same as those already mentioned are as described above.

[0039] The antioxidant composition may also be in the form of a pharmaceutical composition, a quasi-drug composition, or a cosmetic composition. For example, the composition may be used as a cosmetic composition for improving skin condition, or as a pharmaceutical composition for improving or treating the condition of diseases related to skin damage.

[0040] According to one embodiment, the peptide can restore the inhibited activity of fibroblasts and keratinocytes, thereby improving their antioxidant activity. Therefore, the peptide can be used as an active ingredient in antioxidant compositions.

[0041] The antioxidant composition may, for example, be provided in the form of a pharmaceutically effective composition. The pharmaceutically effective composition may also contain, but is not limited to, a pharmaceutically effective amount of the peptide and / or a pharmaceutically acceptable carrier.

[0042] As used herein, the term "pharmaceutical effective amount" may mean an amount sufficient to achieve the preventive or therapeutic efficacy of the pharmaceutical composition for diseases related to skin damage.

[0043] The pharmaceutically acceptable carriers mentioned above are those commonly used in formulation and include, but are not limited to, lactose, dextrose, saccharose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoic acid, propylhydroxybenzoic acid, talc, magnesium stearate, and mineral oil. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0044] The weight ratio between the peptide and the pharmaceutically acceptable carrier may be, for example, 500:1 to 1:500, and may also be, but is not limited to, 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2.

[0045] The aforementioned pharmaceutical composition may further contain, but is not limited to, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspension agents, preservatives, and the like, in addition to the aforementioned components.

[0046] The aforementioned pharmaceutical composition may be administered orally or parenterally, preferably parenterally, and in the case of parenteral administration, it may be administered by intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, local administration, transdermal administration, etc., but is not limited to these.

[0047] The dosage of the aforementioned pharmaceutical composition may be 0.0001 to 1000 μg (micrograms), 0.001 to 1000 μg, 0.01 to 1000 μg, 0.1 to 1000 μg, or 1.0 to 1000 μg per day, but is not limited to these values ​​and can be prescribed in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, medical condition, diet, administration time, route of administration, excretion rate, and response sensitivity.

[0048] The pharmaceutical composition may be manufactured in unit dose form or encapsulated in a multi-dose container by formulating it with pharmaceutically acceptable carriers and / or excipients using a method readily available to a person with ordinary skill in the art to which the invention pertains.

[0049] The dosage form may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granules, tablet or capsule, and may additionally contain a dispersant and / or stabilizer.

[0050] Another embodiment provides a food composition for improving skin condition that contains a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0051] As stated above, any terms or elements mentioned in the description of the peptides that are the same as those already mentioned are as described above.

[0052] The content of the peptide as an active ingredient contained in the food composition can be appropriately and non-restrictively selected depending on the form of the food, the desired use, etc., and can be added in an amount of 0.01 to 15% by weight of the total food weight. Also, for example, in a health beverage composition, it can be added in a ratio of 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 ml. [Effects of the Invention]

[0053] According to one embodiment of the peptide, by promoting the proliferation of fibroblasts and improving the synthesis of extracellular matrix components and skin barrier factors, it can be applied to improve skin conditions, including wrinkle reduction, improved skin elasticity, wound healing, strengthening of the skin barrier, or suppression of skin aging.

[0054] Therefore, a peptide according to one embodiment can be used as an active ingredient in a composition for improving skin condition. [Brief explanation of the drawing]

[0055] [Figure 1] This is the result of adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells and confirming the level of cell proliferation by measuring changes in cell viability. [Figure 2] This study shows the results of adding a peptide consisting of the amino acid sequence of Sequence ID No. 1 to NIH3T3 cells, after which increased expression of the extracellular matrix components Col1a1, fibronectin, and elastin was confirmed. [Figure 3] The expression levels of extracellular matrix components were quantitatively evaluated after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells. Figure 3A shows the results of confirming the expression level of Col1a1, Figure 3B shows the results of confirming the expression level of fibronectin, and Figure 3C shows the results of confirming the expression level of elastin. [Figure 4] This result shows that after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells, an increase in the expression of SIRT-1 and AQP3, which are skin barrier factors, was confirmed. [Figure 5]The expression levels of skin barrier factors were quantitatively evaluated after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells. Figure 5A shows the results of confirming the expression level of SIRT-1, and Figure 5B shows the results of confirming the expression level of AQP3. [Figure 6] This is the result of quantitatively confirming the change in reactive oxygen species levels, which were increased by ultraviolet light, after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells. [Modes for carrying out the invention]

[0056] The present invention will be described in more detail below based on examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

[0057] Example 1. Synthesis of peptides Peptides having the amino acid sequence of SEQ ID NO: 1, as shown in [Table 1] below, were synthesized using an automated peptide synthesizer (Milligen 9050, Millipore, USA), and these synthesized peptides were separated into pure molecules using C18 reversed-phase high-performance liquid chromatography (HPLC) (Waters Associates, USA). The column used was ACQUITY UPLC BEH300C18 (2.1 mm x 100 mm, 1.7 μm, Waters Co., USA).

[0058] [Table 1]

[0059] Example 2. Confirmation of the proliferation-promoting effect on skin cells In this example, the effect of the peptide from this example on skin cell proliferation was confirmed by evaluating the change in the viability of NIH3T3 mouse fibroblasts.

[0060] Specifically, 1 x 10⁶ NIH3T3 cells in a 96-well plate4 After seeding at a density of cells / well, the cells were cultured for 24 hours. Subsequently, the cells were washed once with serum-free DMEM media, and 50 μM or 100 μM of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into 200 μL of the serum-free media. This was then cultured in a CO2 incubator at 37°C for 72 hours. Subsequently, the culture was washed twice with PBS, and then MTT solution was dispensed into each well at a concentration of 0.5 mg / ml. After shielding from light, the culture was cultured in a CO2 incubator at 37°C for 4 hours, and the absorbance was measured at 540 nm using a microplate reader (Molecular Devices, USA).

[0061] As a result, as shown in Figure 1, we confirmed that the peptide consisting of the amino acid sequence of Sequence ID No. 1 promotes the proliferation of fibroblasts.

[0062] Example 3. Confirmation of the effect of wrinkle improvement and elasticity enhancement. In this example, the effects of the peptide from this example on improving intrinsic skin aging, including wrinkle reduction and increased elasticity, were confirmed by evaluating the expression levels of collagen type 1 (Col1a1), fibronectin, elastin, and hyaluronic acid, which are known components of the dermis.

[0063] Specifically, NIH3T3 cells were placed in a 6-well plate in a 3 x 10⁶ arrangement. 5After seeding at a density of cells / well, the cells were cultured for 24 hours. Subsequently, the cells were washed once with serum-free DMEM media, and then 10 μM, 50 μM, or 100 μM of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into 1 mL of the culture medium and cultured in a CO2 incubator at 37°C for 24 hours. Subsequently, the culture was washed twice with PBS, and RNA was isolated from the culture using easy blue (iNtRON, Cat. No.: 17061, Korea). Subsequently, the isolated RNA was reverse transcribed using RT kit (Enzynomics, Cat. No.: RT200, Korea) to synthesize the respective cDNAs. Subsequently, a polymerase chain reaction (PCR) was performed using the synthesized 1 μg cDNA and primers and PCR kits (enzynomics, Cat. No.: P581T, Korea) for Col1a1, fibronectin, or elastin. In this example, the control group was the untreated group, and the positive control group was the group to which IGF was added. The nucleotide sequences of the primers used in this example are shown in Table 2 below.

[0064] [Table 2]

[0065] As a result, as shown in Figures 2 and 3, it was confirmed that the peptide consisting of the amino acid sequence of Sequence ID No. 1 increased the expression of extracellular matrix components Col1a1, fibronectin, and elastin. Through these results, it was found that the peptide according to one example contributes to the improvement of intrinsic skin aging, including wrinkle reduction and increased elasticity, by increasing extracellular matrix components.

[0066] Example 4. Confirmation of skin barrier strengthening effect In this example, the effect of the peptide from this example on strengthening the skin barrier was confirmed by evaluating the expression levels of sirtuin-1 (SIRT-1) or aquaforin-3 (AQP3).

[0067] Specifically, HaCaT cells were placed in a 6-well plate in a 3 x 10⁶ arrangement. 5 After seeding at a density of cells / well, the cells were cultured for 24 hours. Subsequently, the cells were washed once with serum-free DMEM media, and then 10 μM, 50 μM, or 100 μM of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into 1 mL of the culture medium and cultured in a CO2 incubator at 37°C for 24 hours. Subsequently, the culture was washed twice with PBS, and RNA was isolated from the culture using easy blue (iNtRON, Cat. No.: 17061, Korea). Subsequently, the isolated RNA was reverse transcribed using an RT kit (Enzynomics, Cat. No.: RT200, Korea) to synthesize cDNA. Subsequently, a polymerase chain reaction (PCR) was performed using the synthesized 1 μg cDNA, primers for SIRT-1 or AQP3, and a PCR kit (enzynomics, Cat. No.: P581T, Korea). On the other hand, in this embodiment, the control group was the untreated group, and the positive control group was the group to which EGF was added. The nucleotide sequences of the primers used in this embodiment are shown in Table 3 below.

[0068] [Table 3]

[0069] As a result, as shown in Figures 4 and 5, it was confirmed that the peptide consisting of the amino acid sequence of Sequence ID No. 1 increased the expression of SIRT-1 and AQP3, which are skin barrier factors. Through these results, it was found that the peptide according to one example contributes to strengthening the skin barrier and anti-aging of the skin by increasing skin barrier factors.

[0070] Example 5. Confirmation of the effect of reducing reactive oxygen species increased by ultraviolet light. In this example, the effect of the peptide according to one example on the antioxidant effect in damaged skin cells was confirmed by evaluating the change in the level of reactive oxygen species in skin cells that increased due to ultraviolet irradiation.

[0071] Specifically, HaCaT cells are placed in a 6-well plate in a 5x10⁶ arrangement. 5 After seeding at a density of cells / well, the cells were cultured for 24 hours. Subsequently, the cells were washed once with serum-free DMEM media, and then 50 μM or 100 μM of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into 1 mL of the culture medium and cultured in a CO2 incubator at 37°C for 1 hour. Subsequently, the culture was transferred to an e-tube, mixed with 1 mL of PBS, and dispensed into a well plate. Subsequently, 15 mJ / cm2 of ultraviolet light was irradiated onto the HaCaT cells using a UV irradiator (VILBER LOURMAT, Cat No.: 3102-BSU, France). Subsequently, after removing the PBS from the well plate, 900 μL of the culture medium containing the peptide was added and cultured in a CO2 incubator at 37°C for 24 hours. Subsequently, the culture was treated with DCFH-DA (2',7'-dichlorofluorescin diacetate), covered with foil, and incubated in a CO2 incubator at 37°C for 30 minutes. After washing twice with PBS, 500 μL of 1× trypsin / EDTA was added to obtain cells, which were then centrifuged. After washing the centrifuged cells with PBS, the fluorescence values ​​were measured using flow cytometry (FACS, BD, USA). In this example, the control group was the untreated group, the comparison group (NC) was the group irradiated only with ultraviolet light, and the positive control group was the group to which 50 μM Trolox was added.

[0072] As a result, as shown in Figure 6, it was confirmed that the peptide consisting of the amino acid sequence of Sequence ID No. 1 reduced the level of reactive oxygen species in keratinocytes that had increased due to UV irradiation. Through these results, it was found that the peptide according to one example contributes to the antioxidant effect on UV-induced skin cells.

[0073] Dosage Form Example 1: Production of Peptide Nanosomes 50 mg of the peptide from Example 1 was dissolved in 500 ml of distilled water by thorough stirring. The mixture was then mixed with 5 g of lecithin, 0.3 ml of sodium oleate, 50 ml of ethanol, and a small amount of oil. After adjusting the volume with distilled water to a total of 1 L, the mixture was emulsified using a microfluidizer under high pressure to produce peptide nanosomes with a size of approximately 100 nm.

[0074] Dosage form example 2. Softening lotion A softening lotion containing a peptide according to one embodiment and having the following composition was manufactured using a method known in the industry.

[0075] [Table 4]

[0076] Dosage form example 3: Nutritional cream A nutritional cream containing a peptide according to one embodiment and having the following composition was manufactured using a method known in the industry.

[0077] [Table 5]

[0078] Dosage form example 4. Nourishing lotion A nourishing lotion containing a peptide according to one embodiment and having the following composition was manufactured using a method known in the industry.

[0079] [Table 6]

[0080] Dosage Form Example 5: Essence An essence containing a peptide according to one embodiment and having the following composition was prepared using a method known in the industry.

[0081] [Table 7]

[0082] The above description of the present invention is illustrative, and a person with ordinary skill in the art to which the invention pertains will understand that it can be easily modified into other specific forms without altering the technical idea or essential features of the invention. Therefore, the embodiments described above should be understood to be illustrative in all respects and not limiting.

Claims

1. A peptide consisting of the amino acid sequence of SEQ ID NO:

1.

2. The peptide according to claim 1, wherein the N-terminus of the peptide is bonded to one protecting group selected from the group consisting of an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, a butoxycarbonyl group, an allyloxycarbonyl group, and polyethylene glycol (PEG).

3. The C-terminus of the peptide is an amino group (-NH₂). 2 ), tertiary alkyl group and hydrazino (-NHNH) 2 The peptide according to claim 1, which is bonded to any one protecting group selected from the group consisting of ).

4. The peptide according to claim 1, wherein the peptide exhibits one or more of the following characteristics: (a) Promoting the proliferation of fibroblasts; (b) Enhancement of the expression of extracellular matrix components such as collagen type 1 (Col1a1), fibronectin, or elastin; and (c) Enhanced expression of skin barrier factors, sirtuin-1 (SIRT-1) or aquaforin-3 (AQP3).

5. A cosmetic composition for improving skin condition, comprising the peptide described in any one of claims 1 to 4 as an active ingredient.

6. The cosmetic composition according to claim 5, wherein the peptide is formulated into nanosomes.

7. The cosmetic composition according to claim 5, wherein the improvement of skin condition is wrinkle reduction, improvement of skin elasticity, wound healing, strengthening of the skin barrier, or suppression of skin aging.

8. The cosmetic composition according to claim 7, wherein the skin aging is skin aging caused by ultraviolet light.

Images